As you say, it's inherent. I think you're referring to the half-lives. These isotopes have very short half-lives in some cases.
For example, lutetium has a half-life of about five days, give or take. It's currently processed in Germany. Think of it going from Bruce Power to Pearson and over to Germany to be processed, and then to patients, sometimes back in Canada, sometimes abroad. It's really quite a trek.
That is exactly why the CNIC feels so strongly that processing should be happening locally. I'll clarify that I don't mean locally as in 20 minutes away, like McMaster to AtomVie. Several jurisdictions—China is certainly one, but there are others—are doing the complete processing on site where they're producing the isotope. It's under one licence.
Obviously, there would be some regulatory factors that would need to be considered, and I don't have the regulations in front of me, but the key opportunity is really to not just do it locally but to co-locate processing and production. As I mentioned, Bruce Power is beginning to do so with lutetium. That's really the missing piece of the puzzle, in our view. We have the entire isotope supply chain in Canada, here at home, but it's just the processing, particularly on emerging isotopes, that is really the barrier. I would say that's very important.
